Phase 2
Completed N=20
Effect of Quetiapine on Marijuana Withdrawal and Relapse
Marijuana Smoking
Source: ClinicalTrials.gov NCT00743366 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcomePrimary: Measure of Relapse: Change in Puffs Chosen Between Baseline and Relapse Phase — 2.5; 1.5 Puffs
Summary
The objective of this study is to investigate the interaction between marijuana and quetiapine, with the goal of using this information to improve marijuana treatment outcome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Measure of Relapse: Change in Puffs Chosen Between Baseline and Relapse Phase |
2.5; 1.5 | — |
Eligibility Criteria
Inclusion Criteria
- Current marijuana use: average of 2 marijuana cigarettes per day at least 4 times per week for the past 4 weeks
- Able to perform study procedures
- 21-45 years of age
- Women practicing an effective form of birth control (condoms, diaphragm, birth control, pill, IUD)
- Normal body weight
Exclusion Criteria
- Current, repeated illicit drug use (other than marijuana)
- Presence of significant medical illness (e.g., diabetes, cardiovascular disease, hypertension, clinically significant abnormalities)
- History of heart disease or current conduction system disease as indicated by QRS duration > 0.11
- Request for drug treatment
- Current parole or probation
- Pregnancy or current lactation
- Recent history of significant violent behavior
- Major current Axis I psychopathology (major depressive disorder, bipolar disorder, suicide risk, schizophrenia)
- Current use of any prescription or over-the-counter medication
- Prior allergic or otherwise serious adverse reaction to quetiapine
Data sourced from ClinicalTrials.gov (NCT00743366). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.